GINA 哮喘防治指南袖珍本 2009

O Executive Committee (2009)
GINA Assembly (2009)
L - D Eric D. Bateman, M.D., South Africa, Chair IA Louis-Philippe Boulet, M.D., Canada R Alvaro Cruz, M.D., Brazil E Mark FitzGerald, M.D., Canada T Tari Haahtela, M.D., Finland MA Mark Levy, M.D., United Kingdom
RO FOUR COMPONENTS OF ASTHMA CARE .....................................9 REP Component 1. Develop Patient/Doctor Partnership..................9
R Figure 3. Example of Contents of an Action Plan to Maintain O Asthma Control....................................................10
Updated 2009
BASED ON THE GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
®®
GLOBAL INITIATIVE FOR ASTHMA
REPRODUCE!
OR
GLOBAL INITIATIVENOFOT ARLATSETRHMA
IA Scientific information and recommendations for asthma programs. ER • Global Strategy for Asthma Management and Prevention
AT GINA Executive Summary. Eur Respir J 2008; 31: 1-36 M • Pocket Guide for Asthma Management and Prevention for Adults
Publications are available from . This Pocket Guide has been developed from the Global Strategy for Asthma Management and Prevention (Updated 2009). Technical discussions of asthma, evidence levels, and specific citations from the scientific literature are included in that source document.
ATE Component 4. Manage Exacerbations.....................................18 M Figure 8. Severity of Asthma Exacerbations ..........................21
© 2009 Medical Communications Resources, Inc.
TABLE OF CONTENTS PREFACE .......................................................................................2 WHAT IS KNOWN ABOUT ASTHMA?...........................................4 DIAGNOSING ASTHMA ..............................................................6
1
PREFACE
Asthma is a major cause of chronic morbidity and mortality throughout
E! the world and there is evidence that its prevalence has increased C considerably over the past 20 years, especially in children. The Global U Initiative for Asthma was created to increase awareness of asthma OD among health professionals, public health authorities, and the general R public, and to improve prevention and management through a concerted EP worldwide effort. The Initiative prepares scientific reports on asthma, R encourages dissemination and implementation of the recommendations, OR and promotes international collaboration on asthma research. R The Global Initiative for Asthma offers a framework to achieve and TE maintain asthma control for most patients that can be adapted to local AL health care systems and resources. Educational tools, such as laminated T cards, or computer-based learning programs can be prepared that are NO tailored to these systems and resources. O The Global Initiative for Asthma program publications include: L - D • Global Strategy for Asthma Management and Prevention (2009).
TER Component 2. Identify and Reduce Exposure to Risk Factors..11 AL Figure 4. Strategies for Avoiding Common Allergens and T Pollutants ............................................................11
ED Ken Ohta, M.D., Japan T Pierluigi Paggario, M.D., Italy H Soren Pedersen, M.D., Denmark IG Manuel Soto-Quiroz, M.D., Costa Rica COPYR Gary Wong, M.D., Hong Kong ROC
NO Component 3. Assess, Treat, and Monitor Asthma.................12 O Figure 5. Management Approach Based on Control..............14 - D Figure 6. Estimated Equipotent Doses of Inhaled IAL Glucocorticosteroids .............................................15 R Figure 7. Questions for Monitoring Asthma Care ..................17
POCKET GUIDE FOR
ASTHMA MANAGEMENT
AND PREVENTION (for Adults and Children Older than 5 YRe
MATERIAL - DO
COPYRIGHTED
®
A Pocket Guide for Physicians and Nurses
Figure 1. Is it Asthma? ........................................................6
CE! CLASSIFICATION OF ASTHMA BY LEVEL OF CONTROL ...............8 DU Figure 2. Levels of Asthma Control.........................................8
2
Acknowledgements: Grateful acknowledgement is given for unrestricted educational grants from AstraZeneca, Boehringer Ingelheim, Chiesi Group, GlaxoSmithKline, Meda Pharma, Merck Sharp & Dohme, Novartis, Nycomed, PharmAxis and Schering-Plough. The generous contributions of these companies assured that the GINA Committees could meet together and publications could be